Adult T-cell leukemia (ATL) develops via multiple oncogenic steps in human T-cell leukemia virus type I (HTLV-I) carriers. To better understand pathogenesis of ATL, we developed a novel xenogeneic engraftment model in which primary ATL cells are intravenously transplanted into neonatal nonobese diabetic (NOD)/severe-combined immunodeficiency (SCID)/b2-microglobulin null (NOD/SCID/b2m null ) mice. Acute-type ATL cells engrafted in the peripheral blood and in the lymph nodes of recipients at a high efficiency. Engrafted ATL cells were dually positive for human CD4 and CD25, and displayed patterns of HTLV-I integration identical to those of donors by Southern blot analysis. These cells infiltrated into recipients' liver, and formed nodular lesions, recapitulating the clinical feature of each patient. In contrast, in smoldering-type ATL cases, multiple clones of ATL cells engrafted efficiently in NOD/SCID/ b2m null mice. When smoldering-type ATL cells were retransplanted into secondary NOD/SCID/b2m null recipients, single HTLV-I-infected clones became predominant, suggesting that clones with dominant proliferative activity can be competitively selected in this xenogeneic system. Taken together, the NOD/ SCID/b2m null newborn system is useful to understand kinetics, metastasis, and disease progression of ATL in vivo.
Introduction
Adult T-cell leukemia (ATL) is caused by the clonal proliferation of human T-cell leukemia virus type I (HTLV-I)-infected CD4 þ cells. [1] [2] [3] HTLV-I infection is mainly mediated vertically from mothers to their children through breast-feeding. Approximately 2-5% of HTLV-I carriers develop ATL after decades of the latent period, but the mechanism of leukemogenesis is yet to be clarified. 4 Depending on the difference of clinical symptoms and serological characteristics, ATL is classified into four subtypes, acute, lymphoma, smoldering, and chronic types. 5 Although the latter two subtypes are clinically indolent, the majority of smoldering-type ATL patients develop acute-type ATL in a long-term follow-up. 6 Curative treatment is not currently available for acute-type ATL. 7, 8 It is critical to develop a new animal model in order to establish strategies for the treatment of acute type ATL, and prevention of progression from smoldering-to acute-type ATL.
In previous xenogeneic transplantation studies for ATL, HTLV-I-infected cell lines were transplanted into the immunecompromised mice, including CB-17/severe-combined immunodeficiency (SCID), nonobese diabetic (NOD)/SCID and NOD/ SCID/gc null mice. [9] [10] [11] [12] However, it is unclear whether immortalized HTLV-I-infected cells retain the nature of primary ATL cells in a long-term culture. 9, 10 Furthermore, primary acute-type ATL cells did not efficiently engraft in CB-17/SCID mice. 13, 14 Considering vertical infection of HTLV-I, transplantation of HTLV-I-infected cells into newborn mice may mimic the clinical course of ATL. As the insufficient engraftment of primary ATL cells could be due to the residual innate immunity in CB-17/ SCID or NOD/SCID mice, we used NOD/SCID/b2-microglobulin null (NOD/SCID/b2m null ) mice that have low activity of NK cells 15 due to the lack of b2 microglobulin (b2m), the light chain of MHC class I molecule. We have reported that newborn NOD/ SCID/b2m null mice supported significantly higher levels of normal human hematopoiesis as compared to NOD/SCID mice. 16 Both acute-and smoldering-type ATL cells engrafted efficiently in newborn NOD/SCID/b2m null recipients. Engrafted mice showed a monoclonal or polyclonal proliferation of ATL cells in the blood and the lymph nodes according to clinical features specific to each subtype of transplanted ATL. After serial transplantation of hCD4 þ hCD25 þ cells derived from smoldering-type ATL cells, single clone of acute ATL cells were selected in recipients, likely mimicking progression of the smoldering to the acute-type ATL. These findings suggest that the newborn NOD/SCID/b2m null mouse model is useful to analyze pathogenesis of ATL.
Materials and methods
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null (NOD/SCID/b2m null ) mice were developed at the Jackson Laboratory. These mice have been bred and maintained under defined flora with irradiated food and acidified water. All experimental procedures were approved by the Ethical Committee of Kyushu University.
ATL samples
Peripheral blood samples were obtained from ATL patients after written informed consent was obtained. Each patient was diagnosed as ATL based on the presence of anti-HTLV-I antibody in serum, the proliferation of 
Flow cytometric analysis
Antibodies used for flow cytometric analysis were fluorescein isothiocyanate-conjugated anti-human CD4, CD25, CD45 antibodies, and phycoerythrin-conjugated anti-human CD3, CD4, and CD8 antibodies (BD Immunocytometry, San Jose, CA, USA). Samples were analyzed with a FACSCalibur (Becton Dickinson, San Jose, CA, USA).
Cytological and histological analysis
Cytospin specimens of peripheral blood cells in recipient mice were stained by May-Grunwald-Giemsa method. Lymph nodes and liver were fixed with 4% paraformaldehyde for 1 h, dehydrated with 70% ethanol, and embedded in paraffin. Sections (5 mm) were subjected to hematoxylin-eosin staining or immunostaining with anti-human CD4 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Polymerase chain reaction (PCR) and reverse transcription (RT) PCR
To detect HTLV-I genome, primers were designed to amplify the tax region, which is relatively conserved region in the HTLV-I genome. 17 Sense primer for tax is 5 0 -CCC ACT TCC CAG GGT TTG GAC AGA G-3 0 , and antisense primer is 5 0 -CTG TAG AGC TGA GCC GAT AAC GCG-3 0 . The PCR analysis was performed under the condition of 941C for 10 min to denature the DNA, then 30 cycles of 1 min at 941C, 1 min at 631C, and 1 min at 721C. The sequence of PCR products was confirmed by the direct sequencing using ABI Prism 310 (Perkin-Elmer, Wellesley, CA, USA). OKM3T, an HTLV-I-infected cell line, was used as positive control, and HUG-1, a human gastric cancer cell line, was used as negative control. RNA was isolated from hematopoietic tissues of the recipient mice using Isogen (Nippongene, Japan). To examine the transcription of tax in engrafted ATL cells, the following sets of primers were used as described previously. 11 The sense primer for tax/rex was 5 0 -GTC CAA ACC CTG GGA AGT GG-3 0 and antisense primer was 5 0 -GAG CTG ACA ACG CGT CCA TCA-3 0 . The sense primer for b-actin was 5 0 -CAT GGA TGA TGA TAT CGC CG-3 0 . The antisense primer for b-actin was 5 0 -ACA GCC TGG ATA GCA ACG TA-3 0 . The cDNA products were amplified under the condition of 941C for 2 min to denature DNA, then 30 cycles of 1 min at 941C, 1 min at 631C, and 1 min at 721C.
Southern blot analysis
DNA (10 mg) was subjected to Southern blot analysis using nonradioactive probes specific for total HTLV-I genome as reported previously. 18 Briefly, extracted DNA samples from patients and recipient mice were digested with restriction enzyme EcoRI or PstI, separated on 0.8% agarose gels, and transferred onto a nitrocellulose membrane. The membrane was hybridized with digoxigenin (DIG)-labeled probes for HTLV-I genome overnight at 421C. After the wash, the membrane was incubated with alkaline phosphatase-labeled anti-DIG antibody. Disodium 3-(4-methoxyspiro{1, 2-dioxetane-3, 2 0 -(5 0 -chloro) tricycle [3.3.1.1 3.7 ]decan}-4-yl) phenol phosphate was used for autography at room temperature for 1-2 h.
Results
Engraftment of acute-type ATL cells in NOD/SCID/ b2m null mice
As HTLV-I is transmitted mainly from mothers to their neonates, we used newborn mice as recipients. We and others previously showed that NOD/SCID/b2m null mice supported human normal hematopoiesis more efficiently than NOD/SCID mice due to the lower NK cell activity. 15, 16 A total of 10 7 peripheral blood MNCs harvested from acute-type ATL patients were intravenously transplanted into NOD/SCID/b2m null newborns following 1 Gy irradiation. When recipient mice showed morbid signs such as lethargy and ruffled fur at 21-90 days post-transplantation, we killed the mice to analyze the engraftment of ATL cells in recipients (Table 1) . Flow cytometric analysis showed that hCD45 þ hCD3 þ T cells efficiently engrafted in the peripheral blood, the spleen, the lymph node, and the bone marrow of recipients. The majority of engrafted human T cells expressed hCD4 and hCD25 (Figure 1a-c) , which was similar to the phenotypic characteristics of primary ATL cells (Figure 1d ). The engraftment levels of human CD4 þ CD25 þ cells were 22.5730.8% (n ¼ 7) in the blood, 27.6725.2% (n ¼ 8) in the spleen, 6.5713.4% (n ¼ 8) in the bone marrow, and 53.8733.3% (n ¼ 7) in the lymph node (Table 1) . Serum levels of human soluble interleukin-2 receptor (sIL-2R), which have been shown to represent the activity of ATL, 19 were elevated in all recipients, while human sIL-2R was undetectable in nontransplanted control mice.
Cytological and histological analyses of engrafted NOD/SCID/b2m null mice
We next performed morphological analysis of engrafted cells. May-Grunwald-Giemsa staining of cytospin specimens of recipients' blood MNCs showed the presence of cells with multilobulated nuclei, which were referred to as 'flower-like' cells in ATL 1 (Figure 2a ). All recipient mice showed systemic lymphadenopathy (Figure 2b) , and the majority of cells in lymph nodes expressed hCD4 on their surface (Figure 2c and d) . Nodular infiltration of ATL cells expressing hCD4 was found in the liver of some recipients (Figure 2e-g ). Hepatic infiltration of ATL cells in recipients was prominent following the transplantations of ATL cells derived from patients with elevated serum transaminase levels (Patients 1, 3, and 5). Thus, the infiltration of ATL cells into recipients' liver may correlate with an original clinical feature of ATL patients.
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Clonal analysis of acute-type ATL cells in engrafted mice
To confirm that engrafted hCD3 þ hCD4 þ hCD25 þ cells were derived from ATL clones, we analyzed the HTLV-I proviral genome of engrafted cells. The tax region was amplified by PCR using total DNA derived from the bone marrow, the spleen, and the lymph node of engrafted NOD/SCID/b2m null mice. The amplified products were detected at 203 bp in all samples of recipients (Figure 3a) . The sequence analysis showed that these PCR products were confirmed as a part of HTLV-I genome (data not shown).
Although tax is essential for the development of ATL, it has been reported that tax is transcribed only in cultured ATL cells, but not in freshly isolated ATL cells. 11 We isolated RNA from recipients' spleen, and performed RT-PCR for the tax region. Interestingly, tax was not transcribed in engrafted cells but in control immortalized cells (Figure 3b ), indicating that engrafted ATL cells possessed the virological nature of original ATL cells in these patients.
We then performed Southern blot analysis to examine ATL clones in patients and in recipient mice. The number of EcoRIdigested band represents the number of ATL clones. As shown in a representative blot (Figure 3c ), both the original ATL and engrafted cells showed the monoclonal expansion of HTLV-Iinfected cells. Sizes of EcoRI-and PstI-digested bands were identical in patients and in recipients. These results clearly showed that newborn NOD/SCID/b2m null mice supported clonal proliferation of acute-type ATL cells.
Engraftment of smoldering-type ATL cells in NOD/SCID/b2m null mice
It has been reported that only a fraction of HTLV-I-infected clones in smoldering-type ATL can predominantly expand Date were the day of killing when recipient mice got severely sick.
Newborn xenotransplantation assay for primary ATL N Kawano et al resulting in the occurrence of acute-type ATL. 6 In order to examine in vivo nature of smoldering-type ATL cells, we transplanted peripheral blood hCD4 þ cells derived from smoldering-type ATL patients into NOD/SCID/b2m null newborns. All five recipient mice showed efficient engraftment of hCD4 þ hCD25 þ cells (Table 2) , and displayed splenomegaly and lymphadenopathy (Figure 4a and b) . Recipients' blood contained atypical lymphocytes (Figure 4c ) that expressed hCD4 (Figure 4d ). Flow cytometric analysis showed an increased proportion of hCD4 þ hCD25 þ cells in the spleen and the lymph node of recipients as compared to the peripheral blood of patients (Figure 4e and f) . Engraftment levels of hCD4 þ hCD25 þ cells were 53.7726.3% (n ¼ 4) in the blood and 48.2712.9% (n ¼ 4) in the lymph node ( Table 2 ). As shown in Table 3 , more than 10 6 smoldering-type ATL cells were usually required to obtain a significant engraftment. Levels of human sIL-2R were significantly elevated in recipient sera than those in patients' sera ( Table 2 ). PCR analysis demonstrated the presence of RT-PCR analysis was performed to detect tax transcripts in two independent recipients (R1 and R2). (c) Southern blot analysis was performed to evaluate clonality of ATL cells engrafted in recipient mouse. Leukemia cells from a typical ATL patient was used as positive control. HUG was used as a negative control. Genomic DNA derived from controls and the recipient mouse was digested with EcoRI (E) or PstI (P). The clonal proliferation of ATL cells was seen in patient's blood as well as the lymph node of the recipient. The levels of engraftment in hematopoietic tissues were determined by the percentage of human CD4 + CD25 + cells when recipient mice got severely sick.
Newborn xenotransplantation assay for primary ATL N Kawano et al HTLV-I genome in recipients' tissues (Figure 4g) , and Southern blot analysis further confirmed the polyclonal expansion of HTLV-I-infected cells in recipient mice reflecting the original smoldering stage in these ATL patients (Figure 4h) .
In order to examine the long-term behavior of smoldering ATL clones, we further performed a serial transplantation study. hCD4 þ cells isolated from the spleen of two independent primary recipient mice were retransplanted into secondary recipient newborns. During the serial transplantation, the percentage of hCD4 þ hCD25 þ cells was increased (Figure 5a ). Southern blot analysis revealed that HTLV-I-infected T-cell clone was selected in vivo by repeated transplantation into NOD/SCID/b2m null recipients, likely mimicking the progression into acute-type ATL from the smoldering-type ATL (Figure 5b) .
Discussion
In the present study, we describe a novel transplantation assay that can support the highly efficient engraftment of acute and smoldering types of primary ATL cells. Using NOD/SCID/ b2m null newborns as recipients, clonal expansion of primary ATL cells were clearly obtained in the setting of xenogeneic transplantation.
In previous xenotransplant studies for ATL, HTLV-I-infected cell lines, not primary ATL cells, were able to engraft in immune-compromised mice. [9] [10] [11] [12] [13] [14] 20 The administration of recombinant human IL-2 and the addition of neutralizing antimouse IL-2Rb chain antibodies have been tried to increase the engraftment efficiency, but this protocol still could not produce consistent engraftment of acute-type ATL cells.
14 In our study, employing the NOD/SCID/b2m null mouse strain, the use of newborns as donors were especially critical, because when we transplanted the same number of acute-type ATL cells into NOD/SCID/b2m null adults, we did not see successful engraftment of acute-type ATL cells in two independent experiments (data not shown). The advantage of using newborn over adult . DNA was digested with EcoRI (E) or PstI (P). Polyclonal proliferation of ATL cells was seen in the recipient. Table 3 Limiting dilution analysis of smoldering-type ATL cells Newborn xenotransplantation assay for primary ATL N Kawano et al recipients in xenogeneic transplantation has also been emphasized in recent two papers in the RAG2 À/À gc À/À21 and NOD/ SCID/gc À/À22 systems. It is unclear why newborns can provide better engraftment environment than adults in xenogeneic transplantations. In newborn transplants, injected cell doses per body weight should be approximately 10-20 times higher as compared to those in adult transplants. It is also possible that transplantation of cells at a time prior to the initiation of the immune surveillance has a merit for xenogeneic engraftment. As a result, the newborn microenvironment may provide better homing, engraftment, or proliferation of transplanted human leukemia cells. Furthermore, the short lifespan of NOD/SCID/ b2m null mice could be compensated to some extent when newborns are used as recipients.
Acute-and smoldering-type ATL efficiently engrafted in NOD/SCID/b2m null newborns, and showed monoclonal and polyclonal expansion, respectively. Acute-type ATL cells retained their phenotypic and morphological characteristics in recipient mice. In primary transplantation of smoldering-type ATL cells, recipient mice showed splenomegaly, lymphadenopathy, and elevated serum human sIL2-R levels due to polyclonal expansion of smoldering ATL clones. In secondary transplantation of smoldering-type ATL, however, monoclonal expansion of ATL cells was seen in NOD/SCID/b2m null recipients. It is important to understand the mechanism of clonal selection during transmission from the smoldering to the acute phase of ATL patients. It has been reported that transformation into the acute-type ATL even from the carrier stage is occasionally seen in patients treated with immunosuppressant for prevention of rejection after organ transplantations. 23, 24 This suggests that suppression of hosts' immune surveillance may help acute ATL clones to exhibit predominant proliferation, and therefore transplantation of smoldering-type ATL cells into NOD/SCID/b2m null mice may accelerate the process of clonal selection. Our serial transplantation model might be useful to determine the molecular event during this transition, which may contribute to prevention of progression into the acute-type ATL. Thus, the NOD/SCID/b2m null newborn model will provide a potent tool to understand pathogenesis of ATL. Newborn xenotransplantation assay for primary ATL N Kawano et al
